Dusa Pharmaceuticals Inc., said Tuesday that the company has received regulatory approval in Brazil for one of the company's acne products.
Wilmington, Mass.-headquartered Dusa (Nasdaq: DUSA) said the approval is for Levulan Kerastick, a solution to prime the skin, making affected areas more sensitive to light treatment.
Dusa's marketing partner, Stiefel Laboratories Inc. will sell the product in Latin America.
Dusa officials said additional launches of the drug are expected to follow in a number of other Latin American countries, subject to regulatory approvals.
